Navigation Links
U of M begins nation's first clinical trial using T-reg cells from cord blood in leukemia treatment
Date:9/5/2007

University of Minnesota researchers have initiated a ground breaking clinical trial to determine the optimal dose and safety of T regulatory cells (T-regs) to decrease the risk of immune reactions common in patients undergoing blood and marrow transplantation.

Ultimately, the researchers hope the experimental cellular therapy will improve overall survival rates for blood cancer patients as well as offer a potential new paradigm for treating autoimmune diseases.

Toward our quest of making transplants even safer for adults and children with leukemia, lymphoma, multiple myeloma, and other blood and marrow disorders, we are exploring the possibility of using T-regs to enhance the rate of blood and marrow recovery and reduce the risks of graft-versus-host disease, a complication that affects more than 60 percent of patients, said Claudio Brunstein, M.D., principal investigator of the study.

T-regs are a type of lymphocyte, or white blood cell that normally regulates the bodys immune responses. In the case of transplant, donor T-regs may suppress the recipients immune system so that the healthy donors blood-forming stem cells and immune cells can grow, helping ward off life-threatening graft-versus-host-disease (GVHD). GVHD occurs when the immune cells within the donated cells attack the body of the transplant recipient. GVHD causes one-third of deaths after transplant.

Researchers have proven in animal models that infusing T-regs after transplant increases the chance of blood and marrow recovery and decreases the risk of GVHD.

Once we identified that T-regs were highly effective in mouse models, we then spent three years finding ways to make this therapy valuable for transplant patients and potentially useful for patients with autoimmune diseases, said Bruce Blazar, M.D., director of the Center for Translational Medicine at the University.

The T-regs in this study are isolated from umbilical cord blood (blood collected from the placenta or
'/>"/>

Contact: Molly Portz
mportz@umn.edu
612-625-2640
University of Minnesota
Source:Eurekalert

2

GOOD

Page: 1 2

Related biology news :

1. International trial of two microbicides begins
2. NIAID begins clinical trial of West Nile virus vaccine
3. EuroVacc 02 HIV Vaccine Trial Begins
4. Wyoming cloud seeding experiment begins this month
5. Cancer scientists create human leukemia process to map how disease begins, progresses
6. Parents need to be educated about HPV vaccinations for daughters
7. Simple idea to dramatically improve dengue vaccinations
8. Novel therapy combinations gain ground in treating hepatitis
9. New study suggests promising drug combinations for sleeping sickness
10. Failure to meet United Nations sanitation target could affect millions of the worlds poorest
11. Effect on breast tumors of DNA alternations in 3 genes described

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ease (COPD), a respiratory disease commonly known ...leading cause of death worldwide. 600 million peo...to find any real treatment or cure, Grace Parraga ... Western Ontario in London, Canada, is using vario... disease. , Parraga is a scientist in the Im...
(Date:11/20/2009)...researchers report that a class of heart medicatio...mful, effect on the heart, depending on their mole...e journal Circulation Research , found that beta-...ptors on the heart muscle offer the most benefit t...he beta-receptors can actually undermine the struc...
(Date:11/19/2009)..., at the end of the last ice age, North America,s ...conic creatures as mammoths, mastodons, camels, ho... precipitous slide to extinction. , And when the...rsity of large animals equaled or surpassed Africa...entirely novel ecosystem emerged as broadleaved tr...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2Carvedilol shown to have unique characteristics among beta blockers 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Why Do African Americans Fare Worse With Cancer 3F Access and Economics Are Only Part of the Story 4697 1Why Do African Americans Fare Worse With Cancer 3F Access and Economics Are Only Part of the Story 4697 2Why Do African Americans Fare Worse With Cancer 3F Access and Economics Are Only Part of the Story 4697 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 1New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 2New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 4New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 5New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 6Diplomat Specialty Pharmacy 3A Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 50990 1Diplomat Specialty Pharmacy 3A Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 50990 2Diplomat Specialty Pharmacy 3A Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 50990 3
...n human stem cell research, producing embryonic-li...ly speed up the development of treatments for life... The discovery made during a project undertaken wi...anch and the Synthecon Corporation in the United S...with an ethical and reliable source of human stem ...
...-threatening infection in the body, a virus such a...ng, with the cell,s outer membrane. Once inside th...kes over, turning the ,host, cell into a factory t...ll out to invade other cells in the body. , Scient...ith a cell,s membrane, infection of the host cell ...
...he San Francisco VA Medical Center (SFVAMC) and th...ave identified six genes associated with lymphocyt...ative bronchitis (OB), the most common cause of lo...rchers hope their results will lead to an earlier,...or chronic lung rejection, as well as greater unde...
Other Biology News:Insight into the processes of 'positive' and 'negative' learners 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3Researchers identify genes associated with lung transplant rejection 2
(Date:11/18/2009)...en,s University Belfast are developing new sensors... will help in the fight against the threat of terr...l pads to ,swipe, an individual or crime scene to ...ng instrument that can detect the presence of chem...er decisions to be made in response to terrorist t...
(Date:11/18/2009)...Calif., Nov. 18 Masimo...ry(TM) and Measure-Through Motion and Low-Perfusio...e-based Uni.H.A., one of the largest healthcare Gr...signed a multi-year purchasing agreement for "gold...e agreement offers preferred contract pricing to U...
(Date:11/18/2009)...GA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSci...ences product development company that identifies ...er-related products at various stages of developme... nimotuzumab were presented today in a poster at t...r Therapeutics conference in Boston, Massachusetts...
(Date:11/18/2009)...significantly reduces key cardiac enzymes at multi...ted at American Heart Association 2009 Scientific ... Viron Therapeutics Inc., a biotechnology company ...otein therapeutics derived from pathogens, today r...aluating VT-111 (Serp-1), an anti-inflammatory pro...
Breaking Biology Technology:New technology detects chemical weapons in seconds 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4
...scovery at Rensselaer Polytechnic Institute could ... aircraft, watercraft, and automobiles. , Epoxy c... the design of new jets, planes, and other vehicle...ight, which lowers the overall weight of the vehic...t epoxy composites can be brittle, which is detrim...
...etes Care , , IRVINE, Calif., March 26 On March ... its prestigious global diabetes research award. T...vative G1A(TM) Rapid Diabetes Monitoring Index Te...damage caused by excess sugar in the body. , , (P...26/LA89768 ) , , Diabetes is one of the biggest ...
...URAL FUELS INDUSTRIES, INC. (Pink Sheets: VGPR) to...ir rating for the Company to "Fully Compliant", it... OTC Markets categorizes all securities trading ov... inform investors whether an issuer has made adequ...r. Subsequent to NFI,s recent filing, Pink OTC Ma...
Other Biology Technology:Fitter frames: Nanotubes boost structural integrity of composites 2Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech 2Pink OTC Markets Moves Natural Fuels Industries to Top Tier 2
...nterferons are cytopathic effect inhibition assays...types include; tissue culture supernatents; serum ...se assays, one unit is defined as the quantity of ...ytopathic effect of viral infection by 50%. All ...
Guanylyltransferase (5 U/l) from Ambion
...Nebulizers are available in two product models - t...se two models is that the 6000AT+ includes a membr...er aerosol for improved detection limits and reduc...tion limits for a range of elements by 10-40 times...
...Nebulizers are available in two product models - t...se two models is that the 6000AT+ includes a membr...er aerosol for improved detection limits and reduc...tion limits for a range of elements by 10-40 times...
Biology Products: